HSBC Downgrades AstraZeneca (AZN) to Hold Amid Tough Forecast

HSBC downgraded AstraZeneca (AZN) from Buy to Hold, cutting its price target to 13,750p from 16,500p, a roughly 17% reduction. The move follows the failure of AstraZeneca's Wainua Phase 3 trial to meet its primary endpoint in a form of heart disease, which HSBC said undercut the optimistic case behind its prior rating. The bank also flagged uncertainty around upcoming pipeline catalysts, including the SERENA-4 and AVANZAR trials expected later in 2026, as a source of downside risk. This matters for ordinary investors as it signals caution regarding the health of an important player in the pharmaceutical sector.